Conference Reports for NATAP

Glasgow HIV 28 - 31 October 2018 Glasgow, UK Back

Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates       Reported by Jules Levin Glasgow Oct 28-31 2018   J.A. Grobler; Q. Huang; D.J. Hazuda; M.-T. Lai Merck & Co., Inc., Kenilworth, NJ, USA